Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors
2010
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
Global epidemiology and genotype distribution of the hepatitis C virus infection
2014
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
2013
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance
2018 StandoutNobel
Hepatitis B Virus Infection: Epidemiology and Vaccination
2006 Standout
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
2006
Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function
2013 StandoutNobel
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C
2006
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
2010
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment
2006
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
2005
Interferon-based therapy of hepatitis C
2007
Interferon-based therapy for chronic hepatitis C: current and future perspectives
2008
Treating viral hepatitis C: efficacy, side effects, and complications
2006
Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial
2008
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α‐2a and ribavirin
2007
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response
2007
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients
2003
Chronic hepatitis B
2007 Standout
Chronic hepatitis B: Update 2009 #
2009 Standout
Expert opinion on the treatment of patients with chronic hepatitis C
2008
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
2009 StandoutNature
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
2020 Standout
Treatment of Chronic HCV Infection in Special Populations
2006
Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure–activity and resistance relationships; different scaffolds and mutations
2012
SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
2007
IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1
2011
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy
2010
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Diagnosis and management of chronic viral hepatitis: Antigens, antibodies and viral genomes
2008
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells
2008
A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans
2013 StandoutNobel
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
2007
Therapy of Hepatitis C: From Empiricism to Eradication
2006
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
2010
Optimal therapy in genotype 1 patients
2009
Taming a beast: lessons from the domestication of hepatitis C virus
2019 StandoutNobel
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
2010
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Innate Immune Responses to Hepatitis C Virus
2013 StandoutNobel
Replication of hepatitis C virus
2007 StandoutNobel
Antiviral Combination Therapy for Treatment of Chronic Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infection
2008
The HCV IRES pseudoknot positions the initiation codon on the 40S ribosomal subunit
2010 StandoutNobel
Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C
2012
Broadly Neutralizing Immune Responses against Hepatitis C Virus Induced by Vectored Measles Viruses and a Recombinant Envelope Protein Booster
2012 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
2016 StandoutNobel
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
Synthesis and Pharmacokinetics of Valopicitabine (NM283), an Efficient Prodrug of the Potent Anti-HCV Agent 2‘-C-Methylcytidine
2006
Progress towards a hepatitis C virus vaccine
2013 StandoutNobel
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
2013 StandoutNobel
Towards a small animal model for hepatitis C
2009 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design
2013 StandoutNobel
Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants
2009 StandoutNobel
Works of E Ibrányi being referenced
Efficacy of 6 months treatment with PEG-interferon alpha-2b plus ribavirin (P/R) in patients infected with hepatitis C with genotype 1 of low viral load (G1LVL)
2005
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
2005
Prevalence, genotype distribution and outcome of hepatitis C infections among the employees of the Hungarian Central Hospital for Infectious Diseases
2001